1. Home
  2. GRF vs ALDX Comparison

GRF vs ALDX Comparison

Compare GRF & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

N/A

Current Price

$10.11

Market Cap

39.9M

Sector

Finance

ML Signal

N/A

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

N/A

Current Price

$0.66

Market Cap

39.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRF
ALDX
Founded
1989
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
39.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
GRF
ALDX
Price
$10.11
$0.66
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $6.60
AVG Volume (30 Days)
2.5K
★ 1.6M
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 3.70%
N/A
EPS Growth
N/A
★ 40.43
EPS
★ 1.16
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.81
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.50
$0.60
52 Week High
$11.85
$5.93

Technical Indicators

Market Signals
Indicator
GRF
ALDX
Relative Strength Index (RSI) 50.36 30.34
Support Level $10.09 N/A
Resistance Level $10.55 $1.58
Average True Range (ATR) 0.14 0.07
MACD 0.04 0.01
Stochastic Oscillator 74.33 15.60

Price Performance

Historical Comparison
GRF
ALDX

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: